overal ew revenu ep result in-lin better
expect case last quarter growth ew
import product area tavr trans-cathet aortic valv replac
littl expect two tavr updat also slightli neg
ew new ultra centera valv slow start competitor boston
scientif final receiv fda approv lotu valv yesterday
bull thesi ew base entir ew pipelin specif risk tavr
mitral importantli call updat two front clearli
encourag inde despit european launch pascal end
pascal close revenu ew seem suggest potenti upsid
mitral guidanc pascal start run even small base would
materi catalyst view given size market also ew express
confid posit outcom regard pascal litig abbott lab
ew state intent emphas expect posit
outcom base view recent court hear went last week
upcom quarter critic ew view street expect
acceler growth fortun headwind ultra centera like
calm start outlook risk mitral remain strong
approv in-lin assumpt assum take much share
ew reiter buy ew adjust estim
reflect quarter
net dbt
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
edward lifesci leader emerg
field transcathet heart valv replac
one visibl innov excit
market medic devic sector
ew heart valv busi gener
compani total revenu critic care
busi account total sale
almost attent focus
compani today due on-going pioneer
role develop transcathet heart valv
ew stand-alon tavr transcathet
aortic valv replac name one
largest fastest grow med-tech market
current believ tavr stand alongsid
coronari stent core technolog
catheter lab futur
posit ew current pipelin tmvr
see signific potenti catalyst ew
approv indic expans
ew ultra centera tavr valv current control launch ultra
us eu centera eu today ew posit longer
term outlook valv ultra centera contribut much
overal tavr growth quarter suggest slower expect launch
ultra ew convict level ultra eventu replac sapien across globe
time unchang ultra valv differ enough complet
differ differ process aspect exampl ew work
ensur earli procedur success rate good ultra valv ew
receiv posit feedback centera ew similarli receiv posit
feedback valv centera still remain fewer expect center
given training/proctor requir ew plan initi
po base ew ep discount back target
multipl premium peer trade earn think ew trade
signific premium peer due belief potenti mitral tavr
downsid risk price object tavi market develop risk rel
street high expect competit risk relat ew core tavi busi
risk market opportun technolog could smaller
assum upsid risk price object potenti deeper penetr
market larger market opportun model untreat high low
moder risk patient seek tavi given less invas natur
bob hopkin herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
